Y-Prime Names Richard Gastineau Chief Operating Officer

Y-Prime Names Richard Gastineau Chief Operating Officer

MALVERN, Pa., Sept. 9, 2014 /PRNewswire/ -- Y-Prime, Inc., a premier eClinical products and consulting company, today announced the appointment of Richard Gastineau as Chief Operating Officer and General Counsel. Gastineau will lead many of the company's key business operations, including finance, revenue reporting, sales, legal affairs and human resources.

Gastineau is an attorney and accomplished entrepreneur who brings to Y-Prime more than 20 years of progressive success in business, financial and commercial leadership. His record includes the launch and development of several highly successful healthcare companies.

Y-Prime expects to benefit from his experience with venture funding and corporate finance; mergers and acquisitions; strategic planning and corporate development; joint ventures and strategic alliances; corporate operations; and legal and financial management.

"This is a great example of Y-Prime's ability to attract the brightest leaders in clinical research," said Shawn Blackburn, Chief Executive Officer, Y-Prime Inc. "Rich is a seasoned professional, and his track record of leadership and forward thinking in the business of clinical research speaks for itself. He has proven many times over that he knows how to grow successful companies in this space, and we're counting on his leadership to move Y-Prime forward."

Gastineau joins Y-Prime after co-founding Beacon Bioscience Inc., a leading clinical research organization in the medical imaging field. He was the company's President and General Counsel and guided the company through its acquisition by the global clinical research giant ICON, Plc.

Before launching Beacon, Gastineau co-founded Intelligent Imaging Inc., a multinational pharmaceutical research company. He was COO and lead counsel for the company and negotiated the sale of Intelligent Imaging to Quintiles International in 1997. He stayed on with Quintiles as Vice President of Operations through 2000, with global responsibility for strategic development, finance and operations.

Gastineau is a founding partner of Valley Road Ventures, LLC, a business incubator and management consulting company.

"There are great things happening at Y-Prime," said Gastineau. "There is an undeniable energy here that begins with best-in-class people creating best-in-class technologies. Our solutions are on the leading edge of this industry, and they are a reflection of the innovative minds that are building them.

"Our job is to take our momentum and build it tenfold," he said. "We'll do that by developing new solutions that make it easier for clinical researchers to get the most accurate data possible and get it in house efficiently and quickly. That goal is more easily attained when you work with people like ours, who have worked in clinical research and truly understand the challenges the industry faces."

Gastineau currently serves on the boards of several local charities and businesses, including the board of Y-Prime.

He is a graduate of the University of North Carolina, and earned his J.D. from the Ohio Northern University School of Law and his LL.M. in Tax from the Georgetown University School of Law.

About Y-Prime

Y-Prime, Inc. is the leader in software and technology used in clinical research, healthcare and IT. We help organizations use technology to increase productivity, reduce costs, minimize risk and grow strategically. Better information ... faster. Founded in 2006, Y-Prime is headquartered in Malvern, Pa., and can be found at www.y-prime.com. For more information, call 267-620-2000 or email [email protected].

Follow us on Google+, Facebook, Twitter, YouTube and LinkedIn.

Contact:
Abigail Kramer
263 Great Valley Parkway
Malvern, PA
[email protected]

SOURCE Y-Prime

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.